Skip to main content
Premium Trial:

Request an Annual Quote

Thomas Schweins

Premium

Qiagen said this week that it has named Thomas Schweins as its vice president of corporate strategy.

The newly created position, said the company, involves developing, implementing, and monitoring Qiagen’s long-term strategy and market development activities. Schweins will also be responsible for defining the company’s licensing and acquisition strategy, while coordinating and monitoring the firm’s application portfolio.

According to Qiagen, Schweins most recently was with the German branch of The Boston Consulting Group, were he was manager and core team member of the pharma/healthcare and corporate development practice areas.

Prior to this, he was technology manager and assistant to the board at Hoechst/Aventis. Schweins holds a PhD from the Max-Planck-Society and a MSc from the University of Southern California, Los Angeles.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.